SG10201800535XA - Composition comprising two antibodies engineered to have reduced and increased effector function - Google Patents

Composition comprising two antibodies engineered to have reduced and increased effector function

Info

Publication number
SG10201800535XA
SG10201800535XA SG10201800535XA SG10201800535XA SG10201800535XA SG 10201800535X A SG10201800535X A SG 10201800535XA SG 10201800535X A SG10201800535X A SG 10201800535XA SG 10201800535X A SG10201800535X A SG 10201800535XA SG 10201800535X A SG10201800535X A SG 10201800535XA
Authority
SG
Singapore
Prior art keywords
composition
reduced
effector function
increased effector
antibodies engineered
Prior art date
Application number
SG10201800535XA
Inventor
Christian Gerdes
Christian Klein
Valeria G Nicolini
Pablo Umana
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of SG10201800535XA publication Critical patent/SG10201800535XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6853—Carcino-embryonic antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
SG10201800535XA 2012-08-07 2013-08-05 Composition comprising two antibodies engineered to have reduced and increased effector function SG10201800535XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12179473 2012-08-07

Publications (1)

Publication Number Publication Date
SG10201800535XA true SG10201800535XA (en) 2018-02-27

Family

ID=48916069

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201407580YA SG11201407580YA (en) 2012-08-07 2013-08-05 Composition comprising two antibodies engineered to have reduced and increased effector function
SG10201800535XA SG10201800535XA (en) 2012-08-07 2013-08-05 Composition comprising two antibodies engineered to have reduced and increased effector function

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201407580YA SG11201407580YA (en) 2012-08-07 2013-08-05 Composition comprising two antibodies engineered to have reduced and increased effector function

Country Status (20)

Country Link
US (3) US9526797B2 (en)
EP (2) EP2882777B1 (en)
JP (1) JP6290209B2 (en)
KR (2) KR102163588B1 (en)
CN (1) CN104662045B (en)
AR (1) AR092044A1 (en)
AU (2) AU2013301582B2 (en)
BR (1) BR112014030414A2 (en)
CA (1) CA2872195A1 (en)
ES (2) ES2848732T3 (en)
HK (1) HK1210789A1 (en)
IL (1) IL236892B (en)
MX (2) MX365382B (en)
MY (1) MY175687A (en)
NZ (1) NZ702241A (en)
PL (2) PL2882777T3 (en)
RU (1) RU2650788C2 (en)
SG (2) SG11201407580YA (en)
TR (1) TR201816437T4 (en)
WO (1) WO2014023679A1 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY175341A (en) 2010-08-13 2020-06-19 Roche Glycart Ag Anti-fap antibodies and methods of use
DK3489255T3 (en) 2011-02-10 2021-08-23 Roche Glycart Ag Mutated interleukin-2 polypeptides
EA029300B1 (en) * 2011-03-02 2018-03-30 Роше Гликарт Аг Antibody which binds membrane-bound human carcinoembryonic antigen, production and use thereof
EA201892619A1 (en) 2011-04-29 2019-04-30 Роше Гликарт Аг IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS
EP2747781B1 (en) 2011-08-23 2017-11-15 Roche Glycart AG Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
CN104662045B (en) * 2012-08-07 2019-04-05 罗切格利卡特公司 Include two kinds of engineered improved immunotherapies of composition at the antibody with effector functions reduce and raised
WO2014056783A1 (en) 2012-10-08 2014-04-17 Roche Glycart Ag Fc-free antibodies comprising two fab-fragments and methods of use
ES2829499T3 (en) 2013-02-05 2021-06-01 Engmab Sarl Method for the selection of antibodies against BCMA
MX2015010350A (en) 2013-02-26 2015-10-29 Roche Glycart Ag Bispecific t cell activating antigen binding molecules.
CA2891493C (en) 2013-02-26 2022-03-15 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
PE20211533A1 (en) 2014-08-04 2021-08-16 Hoffmann La Roche BISPECIFIC MOLECULES OF UNON TO ANTIGEN ACTIVATING T-CELLS
BR112016030670A2 (en) * 2014-08-29 2017-10-31 Hoffmann La Roche "immunocytokine"
DK3221355T3 (en) 2014-11-20 2020-12-07 Hoffmann La Roche Combination therapy with T cell activating bispecific antigen binding molecules CD3 and folate receptor 1 (FolR1) as well as PD-1 axis binding antagonists
AR106188A1 (en) 2015-10-01 2017-12-20 Hoffmann La Roche ANTI-CD19 HUMANIZED HUMAN ANTIBODIES AND METHODS OF USE
SI3356411T1 (en) 2015-10-02 2021-09-30 F. Hoffmann-La Roche Ag Bispecific antibodies specific for pd1 and tim3
AR106201A1 (en) 2015-10-02 2017-12-20 Hoffmann La Roche BISPECIFIC MOLECULES OF ANTIGEN BINDING TO T-CELL ACTIVATORS
UY37003A (en) 2015-12-04 2017-06-30 Novartis Ag COMPOSITIONS OF ANTIBODY INTEGRATED WITH CYTOQUINE AND METHODS FOR USE IN IMMUNOR REGULATION
KR20180085740A (en) 2015-12-09 2018-07-27 에프. 호프만-라 로슈 아게 Type II anti-CD20 antibodies to reduce the formation of anti-drug antibodies
IL259588B2 (en) 2016-01-08 2023-09-01 Hoffmann La Roche Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
WO2017148880A1 (en) 2016-03-01 2017-09-08 F. Hoffmann-La Roche Ag Obinutuzumab variants having altered cell death induction
ES2947230T3 (en) 2016-03-22 2023-08-03 Hoffmann La Roche Bispecific molecules for protease-activated T lymphocytes
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
SG11201901071TA (en) 2016-08-10 2019-03-28 Univ Ajou Ind Academic Coop Found Cytokine fused to immunoglobulin fc heterodimer and pharmaceutical composition comprising same
JP7022123B2 (en) 2016-09-30 2022-02-17 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Bispecific antibody against CD3
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
CN110520436A (en) 2017-03-15 2019-11-29 潘迪恩治疗公司 Target immunological tolerance
DK3616720T3 (en) 2017-03-29 2021-03-29 Shionogi & Co PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT
WO2018184965A1 (en) * 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
BR112019017329A2 (en) * 2017-04-03 2020-04-14 Hoffmann La Roche immunoconjugates, one or more polynucleotides and vectors, methods for the production of an immunoconjugate, treatment of a disease and for the stimulation of the immune system, composition, use of the immunoconjugate, invention and uses of the composition
RU2766234C2 (en) * 2017-04-04 2022-02-10 Ф. Хоффманн-Ля Рош Аг New bispecific antigen-binding molecules with capability of specifically binding to cd40 and fap
CN116375876A (en) 2017-04-05 2023-07-04 豪夫迈·罗氏有限公司 Bispecific antibodies that specifically bind PD1 and LAG3
EP3630163A4 (en) 2017-05-24 2021-06-09 Pandion Operations, Inc. Targeted immunotolerance
JOP20190271A1 (en) 2017-05-24 2019-11-21 Novartis Ag Antibody-cytokine engrafted proteins and methods of use for immune related disorders
HUE058233T2 (en) 2017-08-03 2022-07-28 Amgen Inc Interleukin-21 muteins and methods of treatment
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
CR20200330A (en) 2018-01-12 2020-12-23 Amgen Inc Anti-pd-1 antibodies and methods of treatment
AU2019218959A1 (en) 2018-02-08 2020-09-03 Genentech, Inc. Bispecific antigen-binding molecules and methods of use
DE202019005887U1 (en) * 2018-07-03 2023-06-14 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
CN113286808A (en) 2018-10-23 2021-08-20 蜻蜓疗法股份有限公司 Heterodimeric Fc fusion proteins
MA54513A (en) 2018-12-21 2022-03-30 Hoffmann La Roche CD28 ANTIGEN BINDING MOLECULES TUMOR TARGETING AGONISTS
WO2020148612A1 (en) 2019-01-14 2020-07-23 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
US11739146B2 (en) 2019-05-20 2023-08-29 Pandion Operations, Inc. MAdCAM targeted immunotolerance
WO2021127487A2 (en) 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
CA3177843A1 (en) 2020-05-13 2021-11-18 John Thomas MULLIGAN Compositions of protein complexes and methods of use thereof
US11780920B2 (en) 2020-06-19 2023-10-10 Hoffmann-La Roche Inc. Antibodies binding to CD3 and CD19

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP2919890B2 (en) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル Single domain ligand, receptor consisting of the ligand, method for producing the same, and use of the ligand and the receptor
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
DE122004000008I1 (en) 1991-06-14 2005-06-09 Genentech Inc Humanized heregulin antibody.
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
ATE295420T1 (en) 1992-02-06 2005-05-15 Chiron Corp MARKER FOR CANCER AND BIOSYNTHETIC BINDING PROTEIN FOR IT
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
PT1034298E (en) 1997-12-05 2012-02-03 Scripps Research Inst Humanization of murine antibody
EP2261229A3 (en) 1998-04-20 2011-03-23 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2270148A3 (en) 1999-04-09 2011-06-08 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
CA2385347C (en) 1999-10-04 2009-12-15 Medicago Inc. Method for regulating transcription of foreign genes
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2433800C (en) 2001-01-05 2016-09-13 Pfizer Inc. Antibodies to insulin-like growth factor i receptor
CN1555411A (en) 2001-08-03 2004-12-15 ���迨�����＼���ɷݹ�˾ Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
CA2456470A1 (en) 2001-08-13 2003-02-27 University Of Southern California Interleukin-2 mutants with reduced toxicity
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
AU2002357784B2 (en) 2001-12-04 2008-07-31 Merck Patent Gmbh Immunocytokines with modulated selectivity
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
KR101001243B1 (en) 2001-12-27 2010-12-17 글리코파이, 인크. Methods to engineer mammalian-type carbohydrate structures
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
DE60336548D1 (en) 2002-04-09 2011-05-12 Kyowa Hakko Kirin Co Ltd CELL WITH REDUCED OR DELETED ACTIVITY OF A PROTEIN INVOLVED IN GDP FUCOSET TRANSPORT
PL373256A1 (en) 2002-04-09 2005-08-22 Kyowa Hakko Kogyo Co, Ltd. Cells with modified genome
CA2481658A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to fcy receptor iiia
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
JPWO2003085118A1 (en) 2002-04-09 2005-08-11 協和醗酵工業株式会社 Method for producing antibody composition
PT1539966E (en) 2002-09-12 2010-09-14 Greenovation Biotech Gmbh Protein production method
EP1944320A1 (en) 2002-12-16 2008-07-16 Genentech, Inc. Immunoglobulin variants and uses thereof
CA2549932C (en) 2002-12-20 2013-08-20 Greenovation Biotech Gmbh Production of heterologous glycosylated proteins in bryophyte cells
AU2004204494B2 (en) 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
ATE475708T1 (en) 2003-01-22 2010-08-15 Glycart Biotechnology Ag FUSION CONSTRUCTS AND THEIR USE FOR THE PRODUCTION OF ANTIBODIES WITH INCREASED FC RECEPTOR BINDING AFFINITY AND EFFECTOR FUNCTION
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
KR100973564B1 (en) * 2003-05-02 2010-08-03 젠코어 인코포레이티드 OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATION
US7579157B2 (en) 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
PL1692182T3 (en) 2003-11-05 2010-09-30 Roche Glycart Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
RU2386638C2 (en) 2004-03-31 2010-04-20 Дженентек, Инк. Humanised anti-tgf-beta-antibody
DK1737891T3 (en) 2004-04-13 2013-03-25 Hoffmann La Roche ANTI-P-selectin ANTIBODIES
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
US7722867B2 (en) 2005-02-07 2010-05-25 Glycart Biotechnology Ag Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
WO2006100582A1 (en) 2005-03-25 2006-09-28 Glycart Biotechnology Ag Antigen binding molecules directed to mcsp and having increased fc receptor binding affinity and effector function
DE102006031143A1 (en) 2006-07-04 2008-01-24 Merck Patent Gmbh fluorosurfactants
EP2038417A2 (en) * 2006-07-06 2009-03-25 Merck Patent GmbH Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
AR062223A1 (en) 2006-08-09 2008-10-22 Glycart Biotechnology Ag MOLECULES OF ADHESION TO THE ANTIGEN THAT ADHER TO EGFR, VECTORS THAT CODE THEM, AND THEIR USES OF THESE
WO2008034473A1 (en) 2006-09-20 2008-03-27 Dge Dr.-Ing. Günther Engineering Gmbh Method and device for separating methane and carbon dioxide from biogas
WO2008076257A2 (en) 2006-12-13 2008-06-26 Schering Corporation Treating cancer with anti-igflr antibody 19d12 = sch 717454
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CA2687117A1 (en) * 2007-05-14 2008-11-27 Biogen Idec Ma Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
US8906356B2 (en) 2007-11-05 2014-12-09 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
SI2235064T1 (en) 2008-01-07 2016-04-29 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
EP2448599A1 (en) * 2009-06-30 2012-05-09 Philogen S.p.A. Immunocytokines in combination with anti-erbb antibodies for the treatment of cancer
ES2534085T3 (en) * 2009-08-17 2015-04-17 Roche Glycart Ag Targeted Immunoconjugates
TWI412375B (en) 2009-08-28 2013-10-21 Roche Glycart Ag Humanized anti-cdcp1 antibodies
CN102741293B (en) 2009-08-31 2015-04-01 罗切格利卡特公司 Affinity-matured humanized anti CEA monoclonal antibodies
SI2506871T1 (en) * 2009-11-30 2016-12-30 Janssen Biotech, Inc. ANTIBODY Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS
RU2560583C2 (en) 2009-12-22 2015-08-20 Рош Гликарт Аг Antibodies to her3 and application thereof
US20110200595A1 (en) * 2010-02-18 2011-08-18 Roche Glycart TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
KR101118448B1 (en) 2010-03-12 2012-03-06 스미토모덴키고교가부시키가이샤 redox flow battery
JP5841149B2 (en) * 2010-08-13 2016-01-13 ロシュ グリクアート アーゲー Anti-tenascin CA2 antibody and method of use
MY175341A (en) * 2010-08-13 2020-06-19 Roche Glycart Ag Anti-fap antibodies and methods of use
CA2824252A1 (en) * 2011-02-10 2012-08-16 Roche Glycart Ag Improved immunotherapy
DK3489255T3 (en) 2011-02-10 2021-08-23 Roche Glycart Ag Mutated interleukin-2 polypeptides
MX336740B (en) 2011-03-29 2016-01-29 Roche Glycart Ag Antibody fc variants.
EA201892619A1 (en) * 2011-04-29 2019-04-30 Роше Гликарт Аг IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS
CN104662045B (en) * 2012-08-07 2019-04-05 罗切格利卡特公司 Include two kinds of engineered improved immunotherapies of composition at the antibody with effector functions reduce and raised

Also Published As

Publication number Publication date
KR102231723B1 (en) 2021-03-26
AR092044A1 (en) 2015-03-18
CN104662045B (en) 2019-04-05
NZ702241A (en) 2018-04-27
ES2848732T3 (en) 2021-08-11
EP2882777B1 (en) 2018-10-10
MX365382B (en) 2019-05-31
HK1210789A1 (en) 2016-05-06
BR112014030414A2 (en) 2018-05-29
RU2015107889A (en) 2016-09-27
US20140072528A1 (en) 2014-03-13
US9526797B2 (en) 2016-12-27
EP3434695A1 (en) 2019-01-30
KR20150034765A (en) 2015-04-03
KR102163588B1 (en) 2020-10-12
WO2014023679A1 (en) 2014-02-13
MX2015001630A (en) 2015-08-14
US20200197492A1 (en) 2020-06-25
US10603360B2 (en) 2020-03-31
MY175687A (en) 2020-07-06
SG11201407580YA (en) 2014-12-30
AU2013301582A1 (en) 2014-11-13
PL2882777T3 (en) 2019-04-30
CN104662045A (en) 2015-05-27
KR20200118220A (en) 2020-10-14
IL236892A0 (en) 2015-03-31
JP6290209B2 (en) 2018-03-07
EP3434695B1 (en) 2020-12-02
CA2872195A1 (en) 2014-02-13
AU2013301582B2 (en) 2018-09-06
PL3434695T3 (en) 2021-05-17
EP2882777A1 (en) 2015-06-17
ES2700978T3 (en) 2019-02-20
AU2018274836A1 (en) 2018-12-20
TR201816437T4 (en) 2018-11-21
US20170056522A1 (en) 2017-03-02
RU2650788C2 (en) 2018-04-17
JP2015525791A (en) 2015-09-07
AU2018274836B2 (en) 2021-01-21
MX2019006362A (en) 2019-09-09
IL236892B (en) 2021-04-29

Similar Documents

Publication Publication Date Title
HK1210789A1 (en) Composition comprising two antibodies engineered to have reduced and increased effector function
IL237625A0 (en) Anti-mcam antibodies, compositions comprising same and uses thereof
HK1207092A1 (en) Anti-hla-b27 antibodies and uses thereof -hla-b27
HRP20190358T1 (en) Anti-asic1 antibodies and uses thereof
HK1216428A1 (en) Platelet-derived growth factor specific antibodies and compositions and uses thereof
HK1210714A1 (en) Antibody formulations and uses thereof
IL235004A0 (en) Anti-fgfr2 antibodies, compositions comprising same and uses thereof
HK1205523A1 (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof ---1(big-et-1)
GB201113770D0 (en) Novel compositions and uses thereof
EP2766804A4 (en) Cross-reference and priority claim to related applications
EP2874641A4 (en) Glutathione-elevating compositions and uses thereof
GB201106357D0 (en) Composition and uses thereof
SG11201502069SA (en) Beta-hydroxy-beta-methylbutryic acid- containing compositions and uses thereof
PL2830587T3 (en) Dermo-protective and dermo-balancing composition
GB201208372D0 (en) Antibodies and uses thereof
GB201120470D0 (en) Compositions and uses thereof